At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
Descartes 11biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
In Brief
A Phase 2 clinical trial evaluating Descartes 11 for Multiple Myeloma. Completed, enrolled 5 participants across 4 sites.
Detailed Summary
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartFeb 2021
Primary CompletionFeb 2022
Study CompletionApr 2022
TodayJul 2026
First PostedJun 17, 2020
Enrollment StartFeb 24, 2021
Primary CompletionFeb 18, 2022
Study CompletionApr 9, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.0 years ago
Interventions
Descartes 11biological
Car T-cells